Online registration possible with just a few documents
Approval certificates also sold for 200,000 to 4 million won

Concerns are growing over the distribution of counterfeit medicines as more consumers buy drugs through short-form video platforms as well as major Chinese e-commerce platforms.


On November 17, China’s Jinan Daily reported that “as more consumers search for and buy medicines on e-commerce platforms such as Douyin, Taobao and Meituan, related content on social networking services (SNS) has also surged,” adding that “some sellers promote their products as ‘the same product sold at pharmacies’ or ‘genuine medicine.’”

AI-generated image.

AI-generated image.

View original image

"Products Consumers Received After Ordering Were Health Supplements, Not Medicines"


However, the products consumers received after placing orders were packaged under names similar to those of genuine medicines, but were in fact health supplements, not medicines. Local industry representatives say that “counterfeit products like these are rampant on e-commerce platforms.”


In China, companies must obtain approval from the National Medical Products Administration to manufacture and sell medicines. However, some companies have reportedly been disguising their products as health supplements, which face lower barriers to entry for production and distribution, to evade the requirements.


The outlet reported that addresses listed on product packaging as manufacturing locations often could not be found in reality. Some manufacturing facilities were even ghost factories that did not exist. One factory had completed renovation work but had yet to begin operating. There were also cases of companies using other firms’ approval certification numbers without authorization.


Lax Oversight System Under Fire... Consumer Confusion and Discontent Grow

The widespread sale of counterfeit medicines in China has sparked controversy. Screenshot of a Chinese online shopping mall.

The widespread sale of counterfeit medicines in China has sparked controversy. Screenshot of a Chinese online shopping mall.

View original image

This market has been able to flourish because of a lax oversight system that fails to catch products with similar names as they freely move through various distribution channels. Online registration was possible with just a few documents. According to the outlet, one association was issuing certificates valid for two years in exchange for annual membership fees ranging from 1,000 yuan (about 200,000 won) to 20,000 yuan (about 4 million won).


A representative of the Henan Health Products Industry and Commerce Association said, “Health products do not require separate administrative approval, so they enter the market like ordinary goods.” Representatives of other associations also explained, “Certificates of compliance with standards are issued according to association standards. Members first commission third-party organizations to conduct risk assessments, after which the association approves them. This does not constitute administrative approval.”


Consumer confusion and discontent are also growing. Mr. Liu said, “When I type a medicine’s name into an online search bar, dozens of products that look exactly alike come up, so I can’t tell them apart,” adding, “The medicine I wanted to buy was classified as a health supplement, so I thought it was counterfeit, but the genuine product turned out to be a prescription drug.” Complaints are also appearing one after another in product reviews, including, “The ingredients are completely different, and even the name is wrong.”


A managing partner at a local law firm pointed out, “The product name and packaging resemble those of another medicine with a national drug approval number. This is a deliberate attempt to capitalize on medicine prices and is highly likely to mislead consumers.”



Zhang Haihong, an expert in medical device regulation at Shanghai University of Medicine & Health Sciences, said, “They are using consumers’ perception that these are medicines to promote products with lower barriers to entry and lure consumers, and the burden will ultimately fall on consumers.” Zhang called on the relevant authorities to conduct thorough post-market inspections and establish stronger regulations on product labeling and platform entry reviews.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing